A Phase II Randomized Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis Treated With Olorofim Plus Baseline Standard of Care or Placebo Plus Baseline Standard of Care (COCCIMETRICS)
COCCIMETRICS: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Measures for Endpoint Derivation in Patients With Progressive or Refractory Disseminated Coccidioidomycosis (DCM) Treated With Olorofim Plus Baseline Standard of Care (SOC) or With Placebo Plus Baseline SOC
The purpose of this study is to test measurement tools (questionnaire about symptoms and a questionnaire about quality of life) to assess usability in the assessment of treatment effectiveness for people with disseminated coccidioidomycosis (DCM).
Studieöversikt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljerad beskrivning
Valley Fever (coccidioidomycosis) is a serious fungal infection that can cause long-lasting symptoms.
Currently marketed antifungal drugs have limitations including limited dosage forms, drug-drug interactions (DDIs), and significant adverse reactions.
Olorofim is an antifungal candidate with a novel mechanism of action offering activity against resistant organisms, differences in safety profile, along with oral route of administration, predictable and reliable pharmacokinetic (PK) profile and limited potential for DDIs.
This study tests whether the Valley Fever-Patient Reported Outcome (VF-PRO) questionnaire can reliably measure symptom impacts and changes over time in patients with severe forms of the disease (disseminated coccidioidomycosis (DCM)). The study will also assess symptoms of DCM and their severity, and whether olorofim, is safe and can help people with DCM when given together with standard antifungal medications (also known as standard-of-care or SOC).
Studietyp
Studietyp
Inskrivning (Beräknad)
Inskrivning
Fas
Fas
- Fas 2
Kontakter och platser
Studiekontakt
Studiekontakt
- Namn: Angela Wardman
- Telefonnummer: +44 (0)161 518 0401
- E-post: awardman@f2g.com
Studera Kontakt Backup
- Namn: Julia Vassiliadou
- Telefonnummer: +44 (0)7557 290308
- E-post: Julia.Vassiliadou@f2g.com
Deltagandekriterier
Urvalskriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Male and female patients, English- or Spanish-speaking, aged ≥18 years and weighing ≥40 kg.
- Patients with progressive or refractory disseminated coccidioidomycosis (DCM) involving extra-pulmonary sites with or without ongoing active disease in lungs.
- Standard of Care therapy for DCM to date has included 2 different triazoles (with or without a course of intravenous amphotericin B).
Exclusion Criteria:
-
Patients who are unconscious.
-
Women who are pregnant or breastfeeding.
-
Known history of allergy, hypersensitivity, or any serious reaction to any component of the study drug.
-
Patients with or planned placement of indwelling CNS devices.
-
Patients receiving intrathecal amphotericin B at the time of study enrolment.
-
Coccidioidomycosis limited to fibro-cavitary pulmonary disease.
-
All bothersome DCM-related symptoms at study entry are due to irreversible damage (e.g., neurologic deficits due to stroke).
-
Other than cutaneous fungal infections treated topically and Pneumocystis jirovecii infections, patients with a second fungal infection requiring systemic antifungal treatment or prophylaxis.
-
Patients with microbiological findings or other potential conditions that are temporally related and suggest a different than study indication etiology for the clinical features.
-
Patients living with Human immunodeficiency virus (HIV) unless for at least 6 months prior to enrollment:
- Are receiving antiretroviral therapy AND
- Have no evidence of current clinical progression resulting from HIV infection.
-
Patients who have received prior treatment with olorofim/F901318.
-
Patients receiving treatment limited to supportive care due to predicted short survival time.
-
Patients with a baseline prolongation of QT using Fridericia's Correction Formula (QTcF) ≥500 msec, or at high risk for QT/QTc prolongation.
-
Evidence of hepatic dysfunction.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Antal vapen
Vapen och interventioner
Deltagargrupp / ArmDeltagargrupp / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: Arm A (olorofim, plus Standard of Care)
Arm A: receives oral olorofim + Standard of Care |
Arm A: Oral olorofim loading dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 followed by a maintenance dose of 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 168 (± 7 days) |
|
Placebo-jämförare: Arm B (placebo comparator, plus Standard of Care)
Arm B: receives olorofim-matched placebo + Standard of Care |
Arm B: Oral olorofim-matched placebo loading dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 followed by a maintenance dose of 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 168 (± 7 days) |
Vad mäter studien?
Primära resultatmått
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change from baseline in Valley Fever - Patient Reported Outcomes (VF-PRO) Mobility domain score
Tidsram: Day 168
|
Change from baseline in VF-PRO Mobility domain score at the Day 168 (Week 24) study visit. Minimum score: Cannot Do; Maximum score: Not at all difficult. Higher score means more able to do the activities related to Mobility. |
Day 168
|
|
Change from baseline in Valley Fever - Patient Reported Outcomes (VF-PRO) Daily Function domain score
Tidsram: Day 168
|
Change from baseline in VF-PRO Daily Function domain score at the Day 168 (Week 24) study visit. Minimum score: Cannot Do; Maximum score: Not at all difficult. Higher score means more able to do the activities related to Daily Function. |
Day 168
|
Sekundära resultatmått
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
To monitor incidence of Adverse Events in both treatment arms
Tidsram: up to the Day 168 study visit and 4-week Follow-up (FU)
|
up to the Day 168 study visit and 4-week Follow-up (FU)
|
|
|
To monitor incidence of Serious Adverse Events in both treatment arms.
Tidsram: up to the Day 168 study visit and 4-week Follow-up (FU)
|
up to the Day 168 study visit and 4-week Follow-up (FU)
|
|
|
% of patients with a reduction in severity of at least one of their most bothersome baseline DCM-related symptoms
Tidsram: Day 28, Day 56, Day 84, Day 112, Day 140, Day 168
|
% of patients with a reduction in severity of at least one of their most bothersome baseline DCM-related symptoms, and no worsening of their other most bothersome baseline DCM-related symptoms, at the Day 28, Day 56, Day 84, Day 112, Day 140 and Day 168 (Weeks 4, 8, 12, 16, 20 and 24) study visits. |
Day 28, Day 56, Day 84, Day 112, Day 140, Day 168
|
Samarbetspartners och utredare
Sponsor
Sponsor
Samarbetspartners
Samarbetspartners
Utredare
Utredare
- Huvudutredare: George R. Thompson, MD, University of California, Davis, School of Medicine
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Studiestart
Primärt slutförande (Beräknad)
Primärt slutförande
Avslutad studie (Beräknad)
Avslutad studie
Studieregistreringsdatum
Först inskickad
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Första postat
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste uppdatering publicerad
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
Andra studie-ID-nummer
- F901318/0037
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .